nach oben

Erschienen in:

05.05.2020 | Article

Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes

verfasst von: Cindy Gueguen, Sandra L. Burke, Benjamin Barzel, Nina Eikelis, Anna M. D. Watson, Jay C. Jha, Kristy L. Jackson, Yusuke Sata, Kyungjoon Lim, Gavin W. Lambert, Karin A. M. Jandeleit-Dahm, Mark E. Cooper, Merlin C. Thomas, Geoffrey A. Head

Erschienen in: Diabetologia | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We determined whether empagliflozin altered renal sympathetic nerve activity (RSNA) and baroreflexes in a diabetes model in conscious rabbits.

Methods

Diabetes was induced by alloxan, and RSNA, mean arterial pressure (MAP) and heart rate were measured before and after 1 week of treatment with empagliflozin, insulin, the diuretic acetazolamide or the ACE inhibitor perindopril, or no treatment, in conscious rabbits.

Results

Four weeks after alloxan administration, blood glucose was threefold and MAP 9% higher than non-diabetic controls (p < 0.05). One week of treatment with empagliflozin produced a stable fall in blood glucose (−43%) and increased water intake (+49%) but did not change RSNA, MAP or heart rate compared with untreated diabetic rabbits. The maximum RSNA to hypotension was augmented by 75% (p < 0.01) in diabetic rabbits but the heart rate baroreflex was unaltered. Empagliflozin and acetazolamide reduced the augmentation of the RSNA baroreflex (p < 0.05) to be similar to the non-diabetic group. Noradrenaline (norepinephrine) spillover was similar in untreated diabetic and non-diabetic rabbits but twofold greater in empagliflozin- and acetazolamide-treated rabbits (p < 0.05).

Conclusions/interpretation

As empagliflozin can restore diabetes-induced augmented sympathetic reflexes, this may be beneficial in diabetic patients. A similar action of the diuretic acetazolamide suggests that the mechanism may involve increased sodium and water excretion.

Nur mit Berechtigung zugänglich

Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39. https://doi.org/10.1016/S0140-6736(18)32590-X CrossRefPubMed

Fitchett D, Inzucchi SE, Cannon CP et al (2019) Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139(11):1384–1395. https://doi.org/10.1161/CIRCULATIONAHA.118.037778 CrossRefPubMed

Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA (2003) Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108(25):3097–3101. https://doi.org/10.1161/01.CIR.0000103123.66264.FE CrossRefPubMed

Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A (2017) Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clin Exp Pharmacol Physiol 44(4):522–525. https://doi.org/10.1111/1440-1681.12725 CrossRefPubMed

Burke SL, Head GA (2003) Method for in vivo calibration of renal sympathetic nerve activity in rabbits. J Neurosci Methods 127(1):63–74. https://doi.org/10.1016/S0165-0270(03)00121-3 CrossRefPubMed

Zola BE, Miller B, Stiles GL, Rao PS, Sonnenblick EH, Fein FS (1988) Heart rate control in diabetic rabbits: blunted response to isoproterenol. Am J Physiol Endocrinol Metab 255(5 Pt 1):E636–E641. https://doi.org/10.1152/ajpendo.1988.255.5.E636 CrossRef

Wang J, Wan R, Mo Y, Zhang Q, Sherwood LC, Chien S (2010) Creating a long-term diabetic rabbit model. Exp Diabetes Res 2010:289614. https://doi.org/10.1155/2010/289614 CrossRefPubMedPubMedCentral

Dorward PK, Riedel W, Burke SL, Gipps J, Korner PI (1985) The renal sympathetic baroreflex in the rabbit. Arterial and cardiac baroreceptor influences, resetting, and effect of anesthesia. Circ Res 57(4):618–633. https://doi.org/10.1161/01.RES.57.4.618 CrossRefPubMed

Burke SL, Lim K, Moretti JL, Head GA (2016) Comparison of sympathetic nerve activity normalization procedures in conscious rabbits. Am J Physiol Heart Circ Physiol 310(9):H1222–H1232. https://doi.org/10.1152/ajpheart.00866.2015 CrossRefPubMed

10.

Ricketts JH, Head GA (1999) A five parameter logistic equation for investigating asymmetry of curvature in baroreflex studies. Am J Physiol Regul Integr Comp Physiol 277(2):R441–R454. https://doi.org/10.1152/ajpregu.1999.277.2.R441 CrossRef

11.

Head GA, Lukoshkova EV, Burke SL, Malpas SC, Lambert EA, Janssen BJ (2001) Comparing spectral and invasive estimates of baroreflex gain. IEEE Eng Med Biol Mag 20(2):43–52. https://doi.org/10.1109/51.917723 CrossRefPubMed

12.

Korner PI, Badoer E, Head GA (1987) Cardiovascular role of the major noradrenergic cell groups in the rabbit: analysis based on 6-hydroxydopamine-induced transmitter release. Brain Res 435(1–2):258–272. https://doi.org/10.1016/0006-8993(87)91609-x CrossRefPubMed

13.

Ludbrook J (1994) Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 28(3):303–311. https://doi.org/10.1093/cvr/28.3.303 CrossRefPubMed

14.

Nagura S, Sakagami T, Kakiichi A, Yoshimoto M, Miki K (2004) Acute shifts in baroreflex control of renal sympathetic nerve activity induced by REM sleep and grooming in rats. J Physiol 558(Pt 3):975–983. https://doi.org/10.1113/jphysiol.2004.064527 CrossRefPubMedPubMedCentral

15.

Holwerda SW, Restaino RM, Manrique C, Lastra G, Fisher JP, Fadel PJ (2016) Augmented pressor and sympathetic responses to skeletal muscle metaboreflex activation in type 2 diabetes patients. Am J Physiol Heart Circ Physiol 310(2):H300–H309. https://doi.org/10.1152/ajpheart.00636.2015 CrossRefPubMed

16.

Straznicky NE, Grima MT, Sari CI et al (2012) Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes 61(10):2506–2516. https://doi.org/10.2337/db12-0138 CrossRefPubMedPubMedCentral

17.

Ninomiya I, Malpas SC, Matsukawa K, Shindo T, Akiyama T (1993) The amplitude of synchronized cardiac sympathetic nerve activity reflects the number of activated pre- and postganglionic fibers in anesthetized cats. J Auton Nerv Syst 45(2):139–147. https://doi.org/10.1016/0165-1838(93)90125-E CrossRefPubMed

18.

Krishnan D, Liu L, Wiebe SA, Casey JR, Cordat E, Alexander RT (2015) Carbonic anhydrase II binds to and increases the activity of the epithelial sodium-proton exchanger, NHE3. Am J Physiol Renal Physiol 309(4):F383–F392. https://doi.org/10.1152/ajprenal.00464.2014 CrossRefPubMed

19.

Solomon R, Weinberg MS, Dubey A (1991) The diurnal rhythm of plasma potassium: relationship to diuretic therapy. J Cardiovasc Pharmacol 17(5):854–859. https://doi.org/10.1097/00005344-199105000-00023 CrossRefPubMed

20.

Mazidi M, Rezaie P, Gao HK, Kengne AP (2017) Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 6(6):e004007. https://doi.org/10.1161/JAHA.116.004007 CrossRefPubMedPubMedCentral

21.

Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ (2016) Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 18(8):783–794. https://doi.org/10.1111/dom.12670 CrossRefPubMed

22.

Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S (2016) Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 15(1):157. https://doi.org/10.1186/s12933-016-0473-7 CrossRefPubMedPubMedCentral

23.

Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61(10):2098–2107. https://doi.org/10.1007/s00125-018-4669-0 CrossRefPubMed

24.

Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920 CrossRefPubMed

25.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRefPubMed

26.

Seravalle G, Mancia G, Grassi G (2014) Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease. High Blood Press Cardiovasc Prev 21(2):89–105. https://doi.org/10.1007/s40292-014-0056-1 CrossRefPubMed

27.

Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP (2010) The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 33(6):521–528. https://doi.org/10.1038/hr.2010.35 CrossRefPubMed

28.

Perin PC, Maule S, Quadri R (2001) Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 23(1–2):45–55. https://doi.org/10.1081/CEH-100001196 CrossRefPubMed

29.

Jordan J, Tank J, Heusser K et al (2017) The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens 11(9):604–612. https://doi.org/10.1016/j.jash.2017.07.005 CrossRefPubMed

Titel: Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes
verfasst von: Cindy Gueguen
Sandra L. Burke
Benjamin Barzel
Nina Eikelis
Anna M. D. Watson
Jay C. Jha
Kristy L. Jackson
Yusuke Sata
Kyungjoon Lim
Gavin W. Lambert
Karin A. M. Jandeleit-Dahm
Mark E. Cooper
Merlin C. Thomas
Geoffrey A. Head
Publikationsdatum: 05.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 7/2020
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-020-05145-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Insulin sensitivity depends on the route of glucose administration

The pore-forming subunit MCU of the mitochondrial Ca2+ uniporter is required for normal glucose-stimulated insulin secretion in vitro and in vivo in mice

Inhibition of the prostaglandin D2–GPR44/DP2 axis improves human islet survival and function

Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study

Inpatient hypoglycaemia: understanding who is at risk

Correction to: Pregnant women with gestational diabetes and with well controlled glucose levels have decreased concentrations of individual fatty acids in maternal and cord serum

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin